The implications of TMSB4X in TIM3 hypermethylation and CD8(+) T cell exhaustion in diffuse large B-cell lymphoma
A gene linked to immune cell exhaustion in lymphoma emerges as a potential biomarker for identifying patients who may benefit from immunotherapy.
Integrating scRNA-seq, DNA methylation, bulk RNA-seq, and IHC data, this study identifies TMSB4X as a hub gene linking somatic mutation and epigenetic dysregulation in TIM3-mediated CD8+ T cell exhaustion in DLBCL. Low TMSB4X expression predicts poor prognosis and inferior chemotherapy response, but may predict ICB responsiveness, providing a candidate biomarker for DLBCL immunotherapy patient selection.
What the study was
- Study design
- Retrospective bioinformatics + scRNA-seq + immunohistochemistry analysis
- Population
- DLBCL patients (scRNA-seq public datasets + immunohistochemistry cohort)
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Scientific Reports
Why it surfaced
Novel epigenetic-immunologic mechanism in DLBCL; bioinformatics + IHC study. No prospective clinical validation. Scored 5.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.